About Advaxis
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
|
|
|
11-50 employees
View all Advaxis employees
|
|
IT Services and IT Consulting
|
|
609-452-9813
|
|
Princeton, New Jersey
|
|
2002
|
Advaxis Alternatives
Frequently Asked Questions about Advaxis
Daniel J O'connor is the CEO of Advaxis.
The decision makers in Advaxis are Daniel J O'connor, Anu Wallecha, Christine Chansky, etc. Click to Find Advaxis decision makers emails.
Advaxis Staff Directory
Search Advaxis Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
